Fandom

Psychology Wiki

Ergot derivatives

34,203pages on
this wiki
Add New Page
Talk0 Share

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Clinical: Approaches · Group therapy · Techniques · Types of problem · Areas of specialism · Taxonomies · Therapeutic issues · Modes of delivery · Model translation project · Personal experiences ·


Ergot derivatives are products derived from ergot a fungus found on cereals and grasses These include:

See alsoEdit

ReferencesEdit

  • A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. (1991). European Neurology Vol 31(5) Sep-Oct 1991, 314-322.
  • Ahlenius, S., & Larsson, K. (1984). Lisuride, LY-141865, and 8-OH-DPAT facilitate male rat sexual behavior via a non-dopaminergic mechanism: Psychopharmacology Vol 83(4) Jul-Aug 1984, 330-334.
  • Albanese, A., & Colosimo, C. (2003). Dihydroergocriptine in Parkinson's disease: Clinical efficacy and comparison with other dopamine agonists: Acta Neurologica Scandinavica Vol 107(5) May 2003, 349-355.
  • Anlezark, G., & Meldrum, B. (1978). Blockade of photically induced epilepsy by "dopamine agonist" ergot alkaloids: Psychopharmacology Vol 57(1) 1978, 57-62.
  • Anlezark, G., Pycock, C., & Meldrum, B. (1976). Ergot alkaloids as dopamine agonists: Comparisons in two rodent models: European Journal of Pharmacology Vol 37(2) Jun 1976, 295-302.
  • Antonaci, F., Pucci, E., Lanfranchi, S., & Sandrini, G. (1994). Pharmacological treatment of migraine attack: A review of the literature: Revue Roumaine de Neurologie et Psychiatrie Vol 32(1) Jan-Mar 1994, 9-20.
  • Arrigo, A., & et al. (1973). Influence of treatment on symptomatology and correlated electroencephalographic (EEG) changes in the aged: Current Therapeutic Research Vol 15(7) Jul 1973, 417-426.
  • Battaglia, A., Bruni, G., Ardia, A., & Sacchetti, G. (1989). Nicergoline in mild to moderate dementia: A multicenter, double-blind, placebo-controlled study: Journal of the American Geriatrics Society Vol 37(4) Apr 1989, 295-302.
  • Battaglia, A., Bruni, G., Sacchetti, G., Pamparana, F., & et al. (1990). A double-blind randomized study of two ergot derivatives in mild to moderate dementia: Current Therapeutic Research Vol 48(4) Oct 1990, 597-612.
  • Bazo, A. J. (1973). An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: Double-blind study: Journal of the American Geriatrics Society Vol 21(2) Feb 1973, 63-71.
  • Bobkova, N. V., Medvinskaya, N. I., Nesterova, I. V., & Arinbasarov, M. U. (2003). Lesioning of spatial memory in mice treated with agroclavin: Neuroscience and Behavioral Physiology Vol 33(4) May 2003, 301-306.
  • Bonuso, S., Di Stasio, E., Marano, E., Covelli, V., & et al. (1994). The antimigraine effect of ergotamine: A role for alpha-adrenergic blockade? : Acta Neurologica Vol 16(1-2) Feb-Apr 1994, 1-10.
  • Borg, V. (1983). Bromocriptine in the prevention of alcohol abuse: Acta Psychiatrica Scandinavica Vol 68(2) Aug 1983, 100-110.
  • Borg, V., & Weinholdt, T. (1982). Bromocriptine in the treatment of the alcohol-withdrawal syndrome: Acta Psychiatrica Scandinavica Vol 65(2) Feb 1982, 101-111.
  • Bovim, G., & Sjaastad, O. (1993). Cervicogenic headache: Responses to nitroglycerin, oxygen, ergotamine and morphine: Headache: The Journal of Head and Face Pain Vol 33(5) May 1993, 249-252.
  • Brambilla, F., & et al. (1983). Bromocriptine therapy in chronic schizophrenia: Effects on symptomatology, sleep patterns, and prolactin response to stimulation: Psychiatry Research Vol 8(3) Mar 1983, 159-169.
  • Burian, E. (1974). An ergot alkaloid preparation (Hydergine) in the treatment of presenile brain atrophy (Alzheimer's disease): Case report: Journal of the American Geriatrics Society Vol 22(3) Mar 1974, 126-128.
  • Buscaino, G. A., Sorge, F., Bussone, G., Frediani, F., & et al. (1991). Preventive treatment of headache with slow-release dihydroergotamine: Comparison of dosage protocols: Current Therapeutic Research Vol 49(6) Jun 1991, 925-935.
  • Carey, R. J. (1983). Bromocriptine promotes recovery of self-stimulation in 6-hydroxydopamine-lesioned rats: Pharmacology, Biochemistry and Behavior Vol 18(2) Feb 1983, 273-276.
  • Cattabeni, F. (1997). Protein kinase C in synaptic plasticity: A molecular target in the treatment of cognitive disorders: Dementia and Geriatric Cognitive Disorders Vol 8(Suppl 1) Jun 1997, 6-11.
  • Chapin, E. (1979). The effect of prolactin on the initiation and long-term retention of placentophagia in female Long-Evans rats: Dissertation Abstracts International.
  • Cittadini, E., & Goadsby, P. J. (2005). Psychiatric side effects during methysergide treatment: Journal of Neurology, Neurosurgery & Psychiatry Vol 76(7) Jul 2005, 1037-1038.
  • Cittadini, E., & Goadsby, P. J. (2006). "Psychiatric side effects during methysergide treatment": Retraction: Journal of Neurology, Neurosurgery & Psychiatry Vol 77(3) Mar 2006, 426.
  • Claus, J. J., de Koning, I., van Harskamp, F., Breteler, M. M. B., Voet, B., Gutzmann, H., et al. (1998). Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy: Clinical Neuropharmacology Vol 21(3) May-Jun 1998, 190-195.
  • Cohen, M. R., Pary, R., & Burns, R. (1987). Hydergine for schizophrenia: Journal of Clinical Psychiatry Vol 48(1) Jan 1987, 39-40.
  • Cools, A. R. (1986). Mesolimbic dopamine and its control of locomotor activity in rats: Differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens: Psychopharmacology Vol 88(4) Apr 1986, 451-459.
  • Corrodi, H., Farnebo, L.-O., Fuxe, K., & Hamberger, B. (1975). Effect of ergot drugs on central 5-hydroxytryptamine neurons: Evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation: European Journal of Pharmacology Vol 30(2) Feb 1975, 172-181.
  • Crook, T. H. (1997). Nicergoline: Parallel evolution of clinical trial methodology and drug development in dementias: Dementia and Geriatric Cognitive Disorders Vol 8(Suppl 1) Jun 1997, 22-26.
  • Cucinotta, D., De Leo, D., Frattola, L., Trabucchi, M., Albizatti, M. G., Beltramelli, A., et al. (1998). Dihydroergokryptine as long-term treatment of Alzheimer type dementia: A multicenter two-year follow-up: Archives of Gerontology and Geriatrics Suppl 6 1998, 103-110.
  • Cucinotta, D., De Leo, D., Frattola, L., Trabucchi, M., & et al. (1996). Dihydroergokryptine vs placebo in dementia of Alzheimer type: Interim results of a randomized multicenter study after a 1-year follow-up: Archives of Gerontology and Geriatrics Vol 22(2) Mar-Apr 1996, 169-180.
  • Cunningham, K. A., Callahan, P. M., & Appel, J. B. (1984). Discriminative stimulus properties of lergotrile: Journal of Pharmacology and Experimental Therapeutics Vol 230(1) Jul 1984, 47-52.
  • Danielczyk, W., Simanyi, B., Forette, F., Orgogozo, J., & et al. (1988). CBM 36-733 (2-methyl-alpha-ergokryptine) in primary degenerative dementia: Results of a European multicentre trial: International Journal of Geriatric Psychiatry Vol 3(2) Apr-Jun 1988, 107-114.
  • Dannaway, F. R., Piper, A., & Webster, P. (2006). Bread of heaven or wines of light: Eutheogenic legacies and esoteric cosmologies: Journal of Psychoactive Drugs Vol 38(4) Dec 2006, 493-503.
  • DeNoble, V. J., Repetti, S. J., Gelpke, L. W., Wood, L. M., & et al. (1986). Vinpocetine: Nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats: Pharmacology, Biochemistry and Behavior Vol 24(4) Apr 1986, 1123-1128.
  • Dourish, C. T., Hutson, P. H., Kennett, G. A., & Curzon, G. (1986). 8-OH-DPAT-induced hyperphagia: Its neural basis and possible therapeutic relevance: Appetite Vol 7(Suppl) 1986, 127-140.
  • Drago, F., Valerio, C., D'Agata, V., Lauria, N., & et al. (1988). Dihydroergocryptine improves behavioral deficits of aged male rats: Neurobiology of Aging Vol 9(3) May-Jun 1988, 285-290.
  • Drago, F., Valerio, C., Scalisi, B., D'Agata, V., & et al. (1988). Dihydroergocristine and memory alterations of aged male rats: Pharmacology, Biochemistry and Behavior Vol 30(4) Aug 1988, 961-965.
  • Dupont, E., Mikkelsen, B., & Jakobsen, J. (1986). Mesulergine in early Parkinson's disease: A double blind controlled trial: Journal of Neurology, Neurosurgery & Psychiatry Vol 49(4) Apr 1986, 390-395.
  • Dzoljic, M. R., Van der Lely, A. J., & Van Mourik, J. B. (1979). Enkephalin-induced myoclonic twitches blocked by ergometrine and potentiated by haloperidol: Psychopharmacology Vol 66(2) Nov 1979, 111-116.
  • El Sobky, A., El Shazly, M., Darwish, A. K., Davies, T., & et al. (1986). Hydergine effect on prolactin and reaction time in dementia: Biological Psychiatry Vol 21(12) Oct 1986, 1229-1230.
  • Evers, S., Gralow, I., Bauer, B., Suhr, B., Buchheister, A., Husstedt, I.-W., et al. (1999). Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidemiologic study: Clinical Neuropharmacology Vol 22(4) Jul-Aug 1999, 201-206.
  • Evers, S., Schmidt, F., Bauer, B., Voss, H., Grotemeyer, K.-H., & Husstedt, I. W. (1999). The impact of ergotamine-induced headache and ergotamine withdrawal on information processing: Psychopharmacology Vol 142(1) Feb 1999, 61-67.
  • Ferrari, F., Baggio, G., & Mangiafico, V. (1987). Effects of imidazole and some imidazole-derivatives on lisuride-induced mounting and aggressiveness: Psychopharmacology Vol 93(1) Sep 1987, 19-24.
  • Fink, H., Morgenstern, R., & Ott, T. (1991). 2-bromolisuride, an ergot derivative, with dopamine antagonistic and serotonin agonistic properties: Pharmacology, Biochemistry and Behavior Vol 38(2) Feb 1991, 321-325.
  • Fioravanti, M., Buckley, A. E., & Agnoli, A. (1987). A multidimensional approach to the assessment of clinical validity in a study on CCVD treatment: Dihydroergocristine versus placebo: Archives of Gerontology and Geriatrics Vol 6(1) Apr 1987, 83-93.
  • Fioravanti, M., & di Cesare, F. (1992). Memory improvements and pharmacological treatment: A method to distinguish direct effects on memory from secondary effects due to attention improvement: International Psychogeriatrics Vol 4(1) Sum 1992, 119-126.
  • Fioravanti, M., Zavattini, C., & Agazzani, D. (1992). The clinical assessment of memory: A clinical study of the effects of dihydroergocristine on patients with cognitive decline: Giornale di Neuropsicofarmacologia Vol 14(4) Jul-Aug 1992, 131-138.
  • Fischer, R. (1975). Transformations of consciousness: A cartography. I: The perception-hallucination continuum: Confinia Psychiatrica Vol 18(4) 1975, 221-244.
  • Florio, T., Ventra, C., Rapana, A., Scorziello, A., & et al. (1991). Dihydroergotoxine treatment improves active avoidance performance and increases dopamine-stimulated adenylate cyclase activity, in young and aged rats: Behavioural Pharmacology Vol 2(1) Feb 1991, 31-36.
  • Franciosi, A., & Zavattini, G. (1994). Dihydroergocristine in the treatment of elderly patients with cognitive deterioration: A double-blind, placebo-controlled, dose-response study: Current Therapeutic Research Vol 55(11) Nov 1994, 1391-1401.
  • Fuxe, K., Fredholm, B. B., Agnati, L. F., & Corrodi, H. (1978). Dopamine receptors and ergot drugs: Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors: Brain Research Vol 146(2) May 1978, 295-311.
  • Gaitz, C. M., Varner, R. V., & Overall, J. E. (1977). Pharmacotherapy for organic brain syndrome in late life: Archives of General Psychiatry Vol 34(7) Jul 1977, 839-845.
  • Gattaz, W. F., & Kollisch, M. (1986). Bromocriptine in the treatment of neuroleptic-resistant schizophrenia: Biological Psychiatry Vol 21(5-6) May 1986, 519-521.
  • Golda, V. (1990). Animal model of anxiety: Effect of DH-ergotoxine in the genetically hypertensive non-obese rats of Koletsky type and in the rats of Wistar strain: Activitas Nervosa Superior Vol 32(3) Sep 1990, 208-209.
  • Golda, V., & Cvak, L. (1994). Bromocriptine, lisuride and terguride alleviate reduced social investigatory behaviour and recognition of conspecific identity in the genetically hypertensive obese rats of Koletsky type: Homeostasis in Health and Disease Vol 35(6) Dec 1994, 288-289.
  • Golda, V., & Petr, R. (1982). Antihypertensive and "anxiolytic" effect of bromocriptine: Measurements in normotensive and genetically hypertensive rats: Activitas Nervosa Superior Vol 24(4) 1982, 202-203.
  • Golda, V., & Petr, R. (1989). Animal model of anxiety: Interaction of nicergoline and scopolamine in the genetically hypertensive rats: Activitas Nervosa Superior Vol 31(1) Apr 1989, 76-77.
  • Golda, V., Petr, R., Rozsival, V., & Suba, P. (1986). Animal model of depression: Imipramine, bromocriptine and lisuride alleviate motor depression: Activitas Nervosa Superior Vol 28(1) 1986, 26-27.
  • Golda, V., Petr, R., Suba, P., & Skopec, F. (1981). Effect of bromocriptine on behaviour, brain and plasma biochemistry: Age and strain dependency: Activitas Nervosa Superior Vol 23(3) Sep 1981, 188-189.
  • Graham, C. E., Struthers, E. J., Hobson, W. C., McDonald, T., & et al. (1991). Postpartum infertility in common chimpanzees: American Journal of Primatology Vol 24(3-4) 1991, 245-255.
  • Haddjeri, N., Seletti, B., Gilbert, F., de Montigny, C., & Blier, P. (1998). Effect of ergotamine on serotonin-modulated responses in the rodent and human brain: Neuropsychopharmacology Vol 19(5) Nov 1998, 365-380.
  • Hamburg, P., Weilburg, J., Cassem, N. H., Cohen, L., & et al. (1986). Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy: Comprehensive Psychiatry Vol 27(4) Jul-Aug 1986, 272-275.
  • Hassan, M. N., Higgins, D., Traub, M., & Fahn, S. (1986). Chronic treatment with bromocriptine induces behavioral supersensitivity in rats: Life Sciences Vol 39(6) Aug 1986, 513-518.
  • Herrmann, W. M., Stephan, K., Gaede, K., & Apeceche, M. (1997). A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia: Dementia and Geriatric Cognitive Disorders Vol 8(1) Jan-Feb 1997, 9-17.
  • Hlinak, Z. (1985). Short-time suppression of sexual behaviour in female rats by lisuride: Activitas Nervosa Superior Vol 27(4) Dec 1985, 251-253.
  • Hlinak, Z. (1987). Lisuride inhibits temporarily sexual behavior in female rats: Pharmacology, Biochemistry and Behavior Vol 27(2) Jun 1987, 211-215.
  • Hlinak, Z., & Dvorska, I. (1984). Sexual behaviour of juvenile male rats injected with lisuride: Behavioural Processes Vol 9(2-3) Apr 1984, 281-291.
  • Holroyd, K. A., Cordingley, G. E., Pingel, J. D., Jerome, A., & et al. (1989). Enhancing the effectiveness of abortive therapy: A controlled evaluation of self-management training: Headache: The Journal of Head and Face Pain Vol 29(3) Mar 1989, 148-153.
  • Holroyd, K. A., Holm, J. E., Hursey, K. G., Penzien, D. B., Cordingley, G. E., Theofanous, A. G., et al. (1988). Recurrent vascular headache: Home-based behavioral treatment versus abortive pharmacological treatment: Journal of Consulting and Clinical Psychology Vol 56(2) Apr 1988, 218-223.
  • Holroyd, K. A., Holm, J. F., Penzien, D. B., Cordingley, G. E., & et al. (1989). Long-term maintenance of improvements achieved with (abortive) pharmacological and nonpharmacological treatments for migraine: Preliminary findings: Biofeedback & Self Regulation Vol 14(4) Dec 1989, 301-308.
  • Hsu, L. L., Samorajski, T., & Claghorn, J. L. (1983). Effects of acute and chronic ethanol and dihydroergotoxine (hydergine) on neurotransmitter enzymes in the brain: Alcoholism: Clinical and Experimental Research Vol 7(3) Sum 1983, 249-255.
  • Jenike, M. A., Albert, M., Baer, L., Gunther, J., & et al. (1990). Ergot mesylates for Alzheimer's disease: A year-long double-blind trial of 3 mg vs 12 mg daily: International Journal of Geriatric Psychiatry Vol 5(6) Nov-Dec 1990, 375-380.
  • Jenike, M. A., Albert, M. S., Heller, H., LoCastro, S., & et al. (1986). Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease: Journal of Clinical Psychiatry Vol 47(5) May 1986, 249-251.
  • Jiang, D. H., Reches, A., Wagner, H. R., & Fahn, S. (1984). Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain: Neuropharmacology Vol 23(3) Mar 1984, 295-301.
  • Johnels, B. (1982). Locomotor hypokinesia in the reserpine-treated rat: Drug effects from the corpus striatum and nucleus accumbens: Pharmacology, Biochemistry and Behavior Vol 17(2) Aug 1982, 283-289.
  • Jouvent, R., & et al. (1983). Antiparkinsonian and antidepressant effects of high doses of bromocriptine: An independent comparison: Journal of Affective Disorders Vol 5(2) May 1983, 141-145.
  • Kehr, W. (1977). Effect of lisuride and other ergot derivatives on monoamingergic mechanisms in rat brain: European Journal of Pharmacology Vol 41(3) Feb 1977, 261-273.
  • Kenny, A. M., & et al. (1986). Bromocriptine holiday: Effects on dopamine receptors and turning behavior in rats: Neurology Vol 36(3) Mar 1986, 400-404.
  • Kimura, K., Akai, T., Nakamura, K., Yamaguchi, M., & et al. (1991). Dual activation by lisuride on central serotonin 5-HT-sub(1A ) and dopamine D-sub-2 receptor sites: Drug discrimination and receptor binding studies: Behavioural Pharmacology Vol 2(2) Apr 1991, 105-112.
  • Krejci, I., Pragerova, H., Schuh, J., & Dlabac, A. (1985). Lisuride, transdihydrolisuride and some other ergot derivatives: Effects on circling and conditioned avoidance behavior: Activitas Nervosa Superior Vol 27(4) Dec 1985, 298-299.
  • Krisch, I., & Bole-Vunduk, B. (1994). Behavioral studies on LEK-8804, a new ergoline derivative with potent 5-HT-sub(1A ) receptor agonist and 5-HT-sub-2 receptor antagonist activity: Pharmacology, Biochemistry and Behavior Vol 47(2) Feb 1994, 301-305.
  • Krisch, I., Bole-Vunduk, B., Pepelnak, M., Lavric, B., & et al. (1994). Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841: Journal of Pharmacology and Experimental Therapeutics Vol 271(1) Oct 1994, 343-352.
  • Kuskowski, M. A., Morley, G., Malone, S. M., Dysken, M. W., & et al. (1990). Hydergine treatment and psychophysiological measures in primary degenerative dementia: Journal of Geriatric Psychiatry and Neurology Vol 3(1) Jan-Mar 1990, 41-47.
  • Lambert, G. A., Lowy, A. J., Boers, P. M., Angus-Leppan, H., & et al. (1992). The spinal cord processing of input from the superior sagittal sinus: Pathway and modulation by ergot alkaloids: Brain Research Vol 597(2) Dec 1992, 321-330.
  • Langemark, M., & Olesen, J. (1984). Drug abuse in migraine patients: Pain Vol 19(1) May 1984, 81-86.
  • Laszy, J., & Sarkadi, A. (1990). Hypoxia-induced sleep disturbance in rats: Sleep: Journal of Sleep Research & Sleep Medicine Vol 13(3) Jun 1990, 205-217.
  • Limmroth, V., May, A., & Diener, H.-C. (1999). Lysine-acetylsalicylic acid in acute migraine attacks: European Neurology Vol 41(2) Feb 1999, 88-93.
  • Lucas, R. N., & Falkowski, W. (1973). Ergotamine and methysergide abuse in patients with migraine: British Journal of Psychiatry Vol 122(567) Feb 1973, 199-203.
  • Mailland, F. G., Poli, A., & Zottino, G. (1987). Drug surveillance of dihydroergocristine in long-term use: Current Therapeutic Research Vol 42(5) Nov 1987, 857-861.
  • Malacco, E., & di Cesare, F. (1992). Effects of dihydroergocristine treatment on carbohydrate tolerance and cognitive function in patients with non-insulin-dependent diabetes: Current Therapeutic Research Vol 51(4) Apr 1992, 515-523.
  • Manev, H., & Pericic, D. (1988). Effects of the potential antidepressant dihydroergosine in rats forced to swim: Influence on plasma corticosterone: Psychoneuroendocrinology Vol 13(6) 1988, 465-469.
  • Manev, H., Pericic, D., & Muck-Seler, D. (1989). Inhibitory influence of dihydroergosine on the aggressiveness of rats and mice: Pharmacology, Biochemistry and Behavior Vol 32(1) Jan 1989, 111-115.
  • Markstein, R., Seiler, M. P., Jaton, A., & Briner, U. (1992). Structure activity relationship and therapeutic uses of dopaminergic ergots: Neurochemistry International Vol 20(Suppl) Mar 1992, 211-214.
  • Marona-Lewicka, D., Kurrasch-Orbaugh, D. M., Selken, J. R., Cumbay, M. G., Lisnicchia, J. G., & Nichols, D. E. (2002). Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine-sub(1A ) receptor-mediated behavioral effects overlap its other properties in rats: Psychopharmacology Vol 164(1) Oct 2002, 93-107.
  • Matossian, M. K. (1982). Ergot and the Salem witchcraft affair: American Scientist Vol 70(4) Jul-Aug 1982, 355-357.
  • Moret, C., & Briley, M. (1986). Dihydroergocristine-induced stimulation of the 5-HT autoreceptor in the hypothalamus of the rat: Neuropharmacology Vol 25(2) Feb 1986, 169-174.
  • Morley, J. E., Levine, A. S., Grace, M., & Kneip, J. (1982). Dynorphin-(1-13), dopamine and feeding in rats: Pharmacology, Biochemistry and Behavior Vol 16(5) May 1982, 701-705.
  • Mueller, P. S. (1985). Neuroleptic malignant syndrome: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 26(8) Aug 1985, 654-662.
  • Nisoli, E., Tonello, C., Imhof, R., Scherschlicht, R., & et al. (1993). Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist: Journal of Pharmacology and Experimental Therapeutics Vol 266(1) Jul 1993, 97-105.
  • Nordin, C. (1985). Bromocriptine in psychiatric practice: A review of the literature: Nordisk Psykiatrisk Tidsskrift Vol 39(2) 1985, 137-145.
  • Numan, M., Leon, M., & Moltz, H. (1972). Interference with prolactin release and the maternal behavior of female rats: Hormones and Behavior Vol 3(1) Mar 1972, 29-38.
  • Ogawa, N., Asanuma, M., Hirata, H., Kondo, Y., & et al. (1993). Cholinergic deficits in aged rat brain are correlated with nicergoline: Archives of Gerontology and Geriatrics Vol 16(2) Mar-Apr 1993, 103-110.
  • Ogawa, N., Nomura, M., Haba, K., Asanuma, M., & et al. (1992). Effects of dihydroergotoxine on central cholinergic neuronal systems and discrimination learning test in aged rats: Brain Research Vol 586(2) Jul 1992, 229-234.
  • Palfai, T., Armstrong, D., & Courtney, C. L. (1984). Effect of l-dopa or bromocriptine on feeding and motor behavior of rats with lesions in the globus pallidus: Physiology & Behavior Vol 33(2) Aug 1984, 283-289.
  • Pfeiffer, R. F., Wilken, K., Glaeske, C., & Lorenzo, A. S. (1985). Low-dose bromocriptine therapy in Parkinson's disease: Archives of Neurology Vol 42(6) Jun 1985, 586-588.
  • Piercey, M. F., Hoffmann, W. E., Vogelsang, G. D., & Travis, M. (1987). Electrophysiological evaluation of a partial agonist of dopamine receptors: Journal of Pharmacology and Experimental Therapeutics Vol 243(1) Oct 1987, 391-396.
  • Pulvirenti, L., & Koob, G. F. (1993). Lisuride reduces psychomotor retardation during withdrawal from chronic intravenous amphetamine self-administration in rats: Neuropsychopharmacology Vol 8(3) May 1993, 213-218.
  • Quinn, N. P., Lang, A. E., Sheehy, M. P., & Marsden, C. D. (1985). Lisuride in dystonia: Neurology Vol 35(5) May 1985, 766-769.
  • Rainer, M., Mucke, H. A. M., Chwatal, K., & Havelec, L. (1996). Alcohol-induced organic cerebral psychosyndromes: Partial reversal of cognitive impairments assisted by dihydroergocristine: Psychopharmacology Vol 127(4) Oct 1996, 365-369.
  • Rosen, H. J. (1975). Mental decline in the elderly: Pharmacotherapy (ergot alkaloids versus papaverine): Journal of the American Geriatrics Society Vol 23(4) Apr 1975, 169-174.
  • Rosenberg, J. H., & Silberstein, S. D. (2005). The Headache of SAH Responds to Sumatriptan: Headache: The Journal of Head and Face Pain Vol 45(5) May 2005, 597-598.
  • Ruggieri, S., Stocchi, F., Carta, A., Bragoni, M., & et al. (1989). One year treatment with Lisuride delivery pump in Parkinson's disease: Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 13(1-2) 1989, 173-183.
  • Sachs, G. S., Gelenberg, A. J., Bellinghausen, B., Wojcik, J., & et al. (1989). Ergoloid mesylates and ECT: Journal of Clinical Psychiatry Vol 50(3) Mar 1989, 87-90.
  • Saletu, B., Anderer, P., & Semlitsch, H. V. (1997). Relations between symptomatology and brain function in dementias: Double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline: Dementia and Geriatric Cognitive Disorders Vol 8(Suppl 1) Jun 1997, 12-21.
  • Saletu, B., Paulus, E., Linzmayer, L., Anderer, P., & et al. (1995). Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG/ERP mapping study: Psychopharmacology Vol 117(4) Feb 1995, 385-395.
  • Samet, C. M. (1976). The evaluation of Bellergal tablets compared to librium and placebo in the treatment of symptoms of anxiety tension states associated with functional gastrointestinal disorders: Psychosomatics: Journal of Consultation Liaison Psychiatry Vol 17(4) 1976, 202-209.
  • Saper, J. R., & Silberstein, S. (2006). Pharmacology of Dihydroergotamine and Evidence for Efficacy and Safety in Migraine: Headache: The Journal of Head and Face Pain Vol 46(Suppl 4) Nov 2006, S171-S181.
  • Scarzella, L., & et al. (1985). Clinical trial on the therapeutic activity of dihydroergokryptine in parkinsonism: Preliminary results: Current Therapeutic Research Vol 38(3) Sep 1985, 432-440.
  • Schechter, M. D. (1984). Evidence for a direct dopaminergic effect of lisuride: Pharmacology, Biochemistry and Behavior Vol 21(2) Aug 1984, 185-189.
  • Schmidt, L. G., Dufeu, P., Kuhn, S., & Rommelspacher, H. (1994). Relapse prevention in alcoholics with an anticraving drug treatment: First results of the Berlin study: Pharmacopsychiatry Vol 27(Suppl 1) Jul 1994, 21-23.
  • Schneider, L. S., & Olin, J. T. (1994). Overview of clinical trials of hydergine in dementia: Archives of Neurology Vol 51(8) Aug 1994, 787-798.
  • Schuh, J., Krejci, I., Pragerova, H., & Dlabac, A. (1985). Effect of lisuride and transdihydrolisuride on stress-induced analgesia in rats: Activitas Nervosa Superior Vol 27(4) Dec 1985, 299-300.
  • Seeldrayers, P., & et al. (1985). CSF levels of neurotransmitters in Alzheimer-type dementia: Effects of ergoloid mesylate: Acta Neurologica Scandinavica Vol 71(5) May 1985, 411-414.
  • Shawcross, W. E. (1983). Recreational use of ergoline alkaloids from Argyreia nervosa: Journal of Psychoactive Drugs Vol 15(4) Oct-Dec 1983, 251-259.
  • Shukla, S., Turner, W. J., & Newman, G. (1985). Bromocriptine-related psychosis and treatment: Biological Psychiatry Vol 20(3) Mar 1985, 326-328.
  • Spiegel, R., Huber, F., & Koberle, S. (1983). A controlled long-term study with ergoloid mesylates (HydergineReg.) in healthy, elderly volunteers: Results after three years: Journal of the American Geriatrics Society Vol 31(9) Sep 1983, 549-555.
  • Stanishevskaya, A. V., Kogan, B. M., Khristolyubova, N. A., & Anokhina, I. P. (1985). Effect of bromocryptine on alcohol consumption and catecholamine content in the brain of rats under long-term alcoholization: Farmakologiya i Toksikologiya Vol 48(3) 1985, 88-91.
  • Stone, T. W. (1974). On the antagonism of ergot alkaloids and dopamine by phenothiazines: Experientia Vol 30(7) 1974, 827-829.
  • Svensson, L. (1985). Effects of 8-OH-DPAT, lisuride and some ergot-related compounds on the acoustic startle response in the rat: Psychopharmacology Vol 85(4) Apr 1985, 469-475.
  • Tamminga, C. A., & Schaffer, M. H. (1979). Treatment of schizophrenia with ergot derivatives: Psychopharmacology Vol 66(3) Dec 1979, 239-242.
  • Taneli, B., & et al. (1986). Bromocriptine-induced schizophrenic syndrome: American Journal of Psychiatry Vol 143(7) Jul 1986, 935.
  • Tfelt-Hansen, P., Saxena, P. R., Dahlof, C., Pascual, J., Lainez, M., Henry, P., et al. (2000). Ergotamine in the acute treatment of migraine: A review and European consensus: Brain: A Journal of Neurology Vol 123(1) Jan 2000, 9-18.
  • Thienhaus, O. J., Wheeler, B. G., Simon, S., Zemlan, F. P., & et al. (1987). A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine-super(R)) in mild dementia: Journal of the American Geriatrics Society Vol 35(3) Mar 1987, 219-223.
  • Toyokura, Y., & et al. (1985). Effects of bromocriptine on parkinsonism: A nation-wide collaborative double-blind study: Acta Neurologica Scandinavica Vol 72(2) Aug 1985, 157-170.
  • Valerio, C., Spadaro, F., Astuto, C., Raffaele, R., & et al. (1989). Dihydroergocristine prevents novelty-induced excessive grooming behavior in aged male rats: New Trends in Experimental & Clinical Psychiatry Vol 5(2) Apr-Jun 1989, 129-140.
  • Verhoeven, W. M., Elderson, A., & Westenberg, H. G. (1985). Neuroleptic malignant syndrome: Successful treatment with bromocriptine: Biological Psychiatry Vol 20(6) Jun 1985, 680-684.
  • Vinar, O., Zapletalek, M., Kazdova, E., Nahunek, K., & et al. (1985). Antidepressant effects of lisuride are not different from effects of amitriptyline and nortriptyline: Activitas Nervosa Superior Vol 27(4) Dec 1985, 249-251.
  • Wainscott, G., Sullivan, F. M., Volans, G. N., & Wilkinson, M. (1992). The outcome of pregnancy in women suffering from migraine. Madison, CT: International Universities Press, Inc.
  • White, F. J. (1986). Comparative effects of LSD and lisuride: Clues to specific hallucinogenic drug actions: Pharmacology, Biochemistry and Behavior Vol 24(2) Feb 1986, 365-379.
  • White, F. J., & Appel, J. B. (1982). Lysergic acid diethylamide (LSD) and lisuride: Differentiation of their neuropharmacological actions: Science Vol 216(4545) Apr 1982, 535-537.
  • Wilcox, J. A. (1995). Psychoactive properties of pergolide: Journal of Psychoactive Drugs Vol 27(2) Apr-Jun 1995, 181-182.
  • Winblad, B. (1997). Altered neurotransmission and signal transduction: Targets for nicergoline treatment: Dementia and Geriatric Cognitive Disorders Vol 8(Suppl 1) Jun 1997, 2-5.
  • Wood, K., & Coppen, A. (1983). Prophylactic lithium treatment of patients with affective disorders is associated with decreased platelet: Journal of Affective Disorders Vol 5(3) Aug 1983, 253-258.
  • Yamagami, S., Hirayama, E., Mui, K., Kioka, T., & et al. (1992). The clinical efficacy of nicergoline against psychotic symptoms in dementia: Current Therapeutic Research Vol 51(4) Apr 1992, 529-535.
  • Yesavage, J. A. (1983). Opportunities for and obstacles to treatments for dementias: Journal of the American Geriatrics Society Vol 31(1) Jan 1983, 59-60.
  • Yesavage, J. A., Hollister, L. E., & Burian, E. (1979). Dihydroergotoxine: 6-Mg versus 3-Mg dosage in the treatment of senile dementia: Preliminary report: Journal of the American Geriatrics Society Vol 27(2) Feb 1979, 80-82.
  • Yoshikawa, M., & et al. (1983). A dose-response study with dihydroergotoxine mesylate in cerebrovascular disturbances: Journal of the American Geriatrics Society Vol 31(1) Jan 1983, 1-7.
  • Zappoli, R., Arnetoli, G., Paganini, M., Versari, A., & et al. (1987). Contingent negative variation and reaction time in patients with presenile idiopathic cognitive decline and presenile Alzheimer-type dementia: Preliminary report on long-term nicergoline treatment: Neuropsychobiology Vol 18(3) 1987, 149-154.

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.

Also on Fandom

Random Wiki